Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children

Caterina Guinovart, John J Aponte, Jahit Sacarlal, Pedro Aide, Amanda Leach, Quique Bassat, Eusébio Macete, Carlota Dobaño, Marc Lievens, Christian Loucq, W Ripley Ballou, Joe Cohen, Pedro L Alonso, Caterina Guinovart, John J Aponte, Jahit Sacarlal, Pedro Aide, Amanda Leach, Quique Bassat, Eusébio Macete, Carlota Dobaño, Marc Lievens, Christian Loucq, W Ripley Ballou, Joe Cohen, Pedro L Alonso

Abstract

Background: The pre-erythrocytic malaria vaccine RTS,S/AS02A has shown to confer protection against clinical malaria for at least 21 months in a trial in Mozambican children. Efficacy varied between different endpoints, such as parasitaemia or clinical malaria; however the underlying mechanisms that determine efficacy and its duration remain unknown. We performed a new, exploratory analysis to explore differences in the duration of protection among participants to better understand the protection afforded by RTS,S.

Methodology/principal findings: The study was a Phase IIb double-blind, randomized controlled trial in 2022 children aged 1 to 4 years. The trial was designed with two cohorts to estimate vaccine efficacy against two different endpoints: clinical malaria (cohort 1) and infection (cohort 2). Participants were randomly allocated to receive three doses of RTS,S/AS02A or control vaccines. We did a retrospective, unplanned sub-analysis of cohort 2 data using information collected for safety through the health facility-based passive case detection system. Vaccine efficacy against clinical malaria was estimated over the first six-month surveillance period (double-blind phase) and over the following 12 months (single-blind phase), and analysis was per-protocol. Adjusted vaccine efficacy against first clinical malaria episodes in cohort 2 was of 35.4% (95% CI 4.5-56.3; p = 0.029) over the double-blind phase and of 9.0% (-30.6-36.6; p = 0.609) during the single-blind phase.

Conclusions/significance: Contrary to observations in cohort 1, where efficacy against clinical malaria did not wane over time, in cohort 2 the efficacy decreases with time. We hypothesize that this reduced duration of protection is a result of the early diagnosis and treatment of infections in cohort 2 participants, preventing sufficient exposure to asexual-stage antigens. On the other hand, the long-term protection against clinical disease observed in cohort 1 may be a consequence of a prolonged exposure to low-dose blood-stage asexual parasitaemia.

Trial registration: ClinicalTrials.gov NCT00197041.

Conflict of interest statement

Competing Interests: MVI supports the development and testing of a number of malaria vaccines, including some that can be regarded as competitors. AL, ML, WRB* and JC are currently employed by GSK Biologicals or *were employed at the time the study was conducted. AL, WRB and JC hold shares in GlaxoSmithKline. JC and WRB are inventors on patents relating to malaria vaccines. None of the other authors in this paper have declared a conflict of interest.

Figures

Figure 1. Kaplan-Meier survival curves for the…
Figure 1. Kaplan-Meier survival curves for the cumulative proportion with at least one episode of clinical malaria during the double-blind and single-blind phases in cohort 2 respectively (ATP cohort).
Figure 2. Kaplan-Meier survival curves for the…
Figure 2. Kaplan-Meier survival curves for the cumulative proportion with at least one episode of clinical malaria during the double-blind and single-blind phases in cohort 2 respectively (ATP cohort).
Figure 3. Study design.
Figure 3. Study design.

References

    1. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 2001;358:1927–1934.
    1. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis. 2001;183:640–647.
    1. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 1997;336:86–91.
    1. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004;364:1411–1420.
    1. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet. 2007;370:1543–1551.
    1. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med. 2008;359:2521–2532.
    1. Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med. 2008;359:2533–2544.
    1. Guinovart C, Alonso PL. Methods for determining vaccine efficacy and effectiveness and the main barriers to developing a fully deployable malaria vaccine. Am J Trop Med Hyg. 2007;77:276–281.
    1. Moorthy V, Reed Z, Smith PG. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine. 2007;25:5115–5123.
    1. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet. 2005;366:2012–2018.
    1. Saute F, Aponte J, Almeda J, Ascaso C, Abellana R, et al. Malaria in southern Mozambique: malariometric indicators and malaria case definition in Manhica district. Trans R Soc Trop Med Hyg. 2003;97:661–666.
    1. Alonso PL, Aponte JJ. Field Trials. In: Doolan DL, editor. Methods in Molecular Medicine, Vol 72: Malaria methods and Protocols. Totowa, NJ: Humana Press, Inc; 2002. pp. 607–616.
    1. Sutherland C, Drakeley C, Schellenberg D. How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions? Malaria Journal. 2007;6:161.
    1. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet. 2002;360:610–617.
    1. John CC, Tande AJ, Moormann AM, Sumba PO, Lanar DE, et al. Antibodies to Pre-erythrocytic Plasmodium falciparum Antigens and Risk of Clinical Malaria in Kenyan Children. J Infect Dis. 2008;197:519–526.
    1. Favila-Castillo L, Monroy-Ostria A, Garcia-Tapia D. Plasmodium chabaudi chabaudi: effect of low parasitaemias on immunity in CB6F1 mice. Exp Parasitol. 1999;92:73–80.
    1. Owusu-Agyei S, Koram KA, Baird JK, Utz GC, Binka FN, et al. Incidence of symptomatic and asymptomatic Plasmodium falciparum infection following curative therapy in adult residents of northern Ghana. Am J Trop Med Hyg. 2001;65:197–203.
    1. Schellenberg D, Menendez C, Aponte JJ, Kahigwa E, Tanner M, et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet. 2005;365:1481–1483.
    1. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. 2002;185:1155–1164.
    1. Alonso PL, Saúte F, Aponte JJ, Gómez-Olivé FX, Nhacolo A, et al. Population and Health in Developing Countries. Ottawa: International Development Research Centre (IDRC); 2002. Manhiça DSS, Mozambique. pp. 189–195. In: INDEPTH, editor.
    1. Alonso P, Smith T, Schellenberg J, Masanja H, Mwankusye S, et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. The Lancet. 1994;344:1175–1181.
    1. Wirtz RA, Ballou WR, Schneider I, Chedid L, Gross MJ, et al. Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. Exp Parasitol. 1987;63:166–172.
    1. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.
    1. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995;14:1707–1723.
    1. Smith T, Schellenberg JA, Hayes R. Attributable fraction estimates and case definitions for malaria in endemic areas. Stat Med. 1994;13:2345–2358.

Source: PubMed

3
Abonnere